Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$298.88M+7696.49%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dajun Yang
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 767
- Beta
- 0.66
- Country
- CN
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -3.40
Financials
Revenue
$298.88M+7696.5%Net Income
$-807.68MEBITDA
$-701.08MFree Cash Flow
$-612.31MEPS (diluted)
$-8.68Shares Outstanding (diluted)
93.31M+621.0%Operating Expenses
$994.82MCash & Debt
$1.90BReturn of Capital
$7.74MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $558.48M | $-1.21B | $-13.56 |
| 2024 | $980.65M | $-405.43M | $-5.36 |
| 2023 | $221.98M | $-925.64M | $-52.48 |
| 2022 | $209.71M | $-882.92M | $-53.60 |
| 2021 | $27.91M | $-782.42M | $-49.12 |
| 2020 | $12.45M | $-677.61M | $-50.24 |
| 2019 | $14.51M | $-1.48B | $-112.04 |
| 2018 | $6.81M | $-345.31M | $-26.68 |
| 2017 | $6.33M | $-118.51M | $-9.16 |
| 2016 | $7.67M | $-107.84M | $-8.32 |
Valuation
AAPGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (4)
- Newsmarketbeat.com·23h ago·Neutral
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight Small-cap companies are accustomed to living in the shadow of mega-cap tech firms, but there are signs that the market backdrop could be changing for some of these companies. Investors have been looking beyond the Magnificent Seven for growth opportunities, and smaller companies with improving fundamentals, unique business models, or other noteworthy catalysts may finally have an opportunity to win investor attention.
View source ↗ - Newsseekingalpha.com·46d ago·Positive
Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·46d ago·Neutral
Ascentage Pharma Group International H1 Earnings Call Highlights Ascentage Pharma Group International NASDAQ: AAPG reported first-half 2026 revenue growth as it continued investing in global registrational studies for its hematology-oncology pipeline and began building commercial capabilities outside China.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates Revenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr.
View source ↗
Earnings
Wed, Mar 31(in 6 months)
Consensus estimate $-0.33 per share
Typical surprise -491.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 18$-1.30 vs $-0.22miss
- Tue, Mar 24$-0.65 vs $-0.83beat
- Thu, Mar 27$-1.00 vs $0.02miss
Estimates and results for AAPG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AAPG officers and directors.
No open-market trades in the recent filings. All 72 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AAPG.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.